{"contentid": 488656, "importid": NaN, "name": "R-Pharm to produce AstraZeneca vaccine in Russia", "introduction": "The Russian drugmaker R-Pharm will start the production of UK-based AstraZeneca\u00e2\u0080\u0099s COVID-19 vaccine at its facilities in Russia starting in June of the current year, according to recent statements by R-Pharm\u00e2\u0080\u0099s chief executive Vasily Ignatiev, as well as local media, reports the Pharma Letters local correspondent.", "content": "<p>The Russian drugmaker R-Pharm will start the production of UK-based AstraZeneca&rsquo;s (LSE: AZN) COVID-19 vaccine at its facilities in Russia starting in June of the current year, according to recent statements by R-Pharm&rsquo;s chief executive Vasily Ignatiev, as well as local media, reports the Pharma Letters local correspondent.&nbsp;</p>\n<p>The vaccine, initially named COVID-19 Vaccine AstraZeneca, but now known as Vaxzevria, will be intended for exports only and will not be supplied to the Russian market.&nbsp;</p>\n<p>As Mr Ignatiev noted, the output of the new production will amount to several hundred thousand doses a month. So far, an interest in the vaccine has been expressed by countries of the Persian Gulf, which are expected to become its major buyers.&nbsp;</p>\n<p>The deliveries of the vaccine will be conducted by R-Pharm together with the Russian Fund of Direct Investments (RFDI), Russia's sovereign wealth fund established to make investments in leading companies of high-growth sectors of the Russian economy.&nbsp;</p>\n<p>In July 2020, head of the RFDI, Kirill Dmitriev, announced that R-Pharm would produce a vaccine from AstraZeneca and Oxford University. According to him, that will take place on the basis of commercial agreement, that was signed between the two companies.</p>\n<p>Alexei Repik, R-Pharm&rsquo;s founder and chairman explained that under the terms of the agreement R-Pharm will provide technological facilities for the new production. He added that R-Pharm will act as a hub for the deliveries of the vaccine to dozens of countries, including the Middle East, Southeast Asia and Europe.</p>\n<h2><strong>Combined vaccines studies</strong>&nbsp;</h2>\n<p>In the meantime, at the end of 2020, another agreement was reached between AstraZeneca, RFDI, R-Pharm as well as the Gamaleya Center on the development and implementation of a clinical trial program for the combined vaccines from AstraZeneca and Sputnik V. Studies of the combined two-component vaccine began in February 2021.<br /><br /> In addition, according to the Russian state register of medicines, clinical trials of the third phase of the AstraZeneca vaccine are planned in Russia with the participation of 150 people and will be conducted on four sites within the territory of the country. However, as the local business paper Izvestia reported in September 2020, citing a specialist at one of the sites, the tests were suspended.</p>", "date": "2021-05-18 11:43:00", "meta_title": "R-Pharm to produce AstraZeneca vaccine in Russia", "meta_keywords": "R-Pharm, AstraZeneca, COVID-19 vaccine, Vaxzevria,  Russia, Production, Trials, Combination, Sputnik V", "meta_description": "R-Pharm to produce AstraZeneca vaccine in Russia", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-18 11:41:22", "updated": "2021-05-18 11:53:40", "access": NaN, "url": "https://www.thepharmaletter.com/article/r-pharm-to-produce-astrazeneca-vaccine-in-russia", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "r-pharmusbig.png", "image2id": "r-pharmussmall.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, From our correspondent, In Depth, Production, Research", "geography_tag": "Russia, UK", "company_tag": "AstraZeneca, Gamaleya, R-Pharm", "drug_tag": "COVID-19 Vaccine AstraZeneca, Sputnik V, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-18 11:43:00"}